Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
Selective delivery of lethal levels of drugs to tumors, without concomitant damage to normal tissues, is a major challenge in cancer chemotherapy. Prodrugs used in conjunction with enzyme-monoclonal antibody conjugates that can target tumors and convert prodrugs to their active drug forms in situ, offer exceptional promise in achieving this objective. Synthesis of prodrugs, acquisition of appropriate enzymes and monoclonal antibodies, and manufacture of conjugates afford considerable flexibility in experimental design.
Huennekens
F M
FM
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D057487:Enzyme Therapy; D004798:Enzymes / Q000276:immunology; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011355:Prodrugs / Q000008:administration & dosage* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004798:Enzymes; D011355:Prodrugs